The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma
Open accessAbstract
Recent literature suggested that cells of the microenvironment of tumors could be abnormal as well. To address this hypothesis in multiple myeloma (MM), we studied bone marrow mesenchymal stem cells (BMMSCs), the only long-lived cells of the bone marrow microenvironment, by gene expression profiling and phenotypic and functional studies in three groups of individuals: patients with MM, patients with monoclonal gamopathy of undefined significance (MGUS) and healthy age-matched subjects. Gene expression profile independently classified the BMMSCs of these individuals in a normal and in an MM group. MGUS BMMSCs were interspersed between these two groups. Among the 145 distinct genes differentially expressed in MM and normal BMMSCs, 46% may account for a tumor-microenvironment cross-talk. Known soluble factors implicated in MM pathophysiologic features (i.e. IL (interleukin)-6, DKK1) were revealed and new ones were found which are involved in angiogenesis, osteogenic differentiation or tumor growth. In particular, GDF15 was found to induce dose-dependent growth of MOLP-6, a stromal cell-dependent myeloma cell line. Functionally, MM BMMSCs induced an overgrowth of MOLP-6, and their capacity to differentiate into an osteoblastic lineage was impaired. Thus, MM BMMSCs are abnormal and could create a very efficient niche to support the survival and proliferation of the myeloma cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Secretion of elevated levels of IL-6 by MSC has been detected upon interaction with malignant cells in several epithelial, hematopoietic and mesenchymal cancers (Table 2) [43, 69, 76, 77, 82, 115–119].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [77]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Notably, MM-MSCs have different gene profiles from their counterparts in normal MSCs [289, 290].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [289]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citationStromal fibroblasts in cancer initiation and progression
Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004) · Nature · doi:10.1038/nature03096 · Cited by 2,354
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,330
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Gregory, C. A., Gunn, W., Peister, A., & Prockop, D. J. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.02.002 · Cited by 1,568
Tian, E., Zhan, F., Walker, R. C., Rasmussen, E., Ma, Y., Barlogie, B., & Shaughnessy, J. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030847 · Cited by 1,505
Molecular characterization of the tumor microenvironment in breast cancer
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.010 · Cited by 1,299
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Self-citationSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817
Cited by
Sorted by citations
No place like home: anatomy and function of the stem cell niche
Jones, D. L., & Wagers, A. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2319 · Cited by 830
Raab, M. S., Podar, K., Breitkreutz, I., Richardson, P. G. G., & Anderson, K. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60221-x · Cited by 713
Targeting the bone marrow microenvironment in multiple myeloma
Kawano, Y., Moschetta, M., Manier, S., Glavey, S. V., Görgün, G., Roccaro, A. M., Anderson, K. C., & Ghobrial, I. M. (2014) · Immunological Reviews · doi:10.1111/imr.12233 · Cited by 394
Bone marrow microenvironment and the identification of new targets for myeloma therapy
Podar, K., Chauhan, D., & Anderson, K. C. (2008) · Leukemia · doi:10.1038/leu.2008.259 · Cited by 341
Treatment of Inflammatory Diseases with Mesenchymal Stem Cells
Newman, R., Yoo, D. S., LeRoux, M. A., & Danilkovitch‐Miagkova, A. (2009) · Inflammation & Allergy - Drug Targets · doi:10.2174/187152809788462635 · Cited by 309
Cho, S., Anderson, K. C., & Tai, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01821 · Cited by 302
Tabera, S., Perez-Simon, J. A., Diez-Campelo, M., Sanchez-Abarca, L. I., Blanco, B., Lopez, A., Benito, A., Ocio, E., Sanchez-Guijo, F. M., Canizo, C., et al. (2008) · Haematologica · doi:10.3324/haematol.12857 · Cited by 283
Zhuang, W., Ge, X., Yang, S., Huang, M., Zhuang, W., Chen, P., Zhang, X., Fu, J., Qu, J., & Li, B.-Z. (2015) · Stem Cells · doi:10.1002/stem.1989 · Cited by 275
Zahir, N., & Tuan, R. S. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21940 · Cited by 279
Mesenchymal stem cells for clinical application
Sensebé, L., Krampera, M., Schrezenmeier, H., Bourin, P., & Giordano, R. (2009) · Vox Sanguinis · doi:10.1111/j.1423-0410.2009.01227.x · Cited by 264
Self-citationConcise Review: Adult Multipotent Stromal Cells and Cancer: Risk or Benefit?
Lazennec, G., & Jørgensen, C. (2008) · Stem Cells · doi:10.1634/stemcells.2007-1006 · Cited by 261
The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape
de Jong, M. M. E., Kellermayer, Z., Papazian, N., Tahri, S., Hofste op Bruinink, D., Hoogenboezem, R., Sanders, M. A., van de Woestijne, P. C., Bos, P. K., Khandanpour, C., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00931-3 · Cited by 250
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
García-Ortiz, A., Rodríguez-García, Y., Encinas, J., Maroto-Martín, E., Castellano, E., Teixidó, J., & Martínez-López, J. (2021) · Cancers · doi:10.3390/cancers13020217 · Cited by 238
Concise Review: Growth Differentiation Factor 15 in Pathology: A Clinical Role?
Corre, J., Hébraud, B., & Bourin, P. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2013-0055 · Cited by 208
Self-citationThe bone marrow microenvironment – Home of the leukemic blasts
Shafat, M. S., Gnaneswaran, B., Bowles, K. M., & Rushworth, S. A. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.03.004 · Cited by 185
Mesenchymal stem cell secretome and regenerative therapy after cancer
Zimmerlin, L., Park, T. S., Zambidis, E. T., Donnenberg, V. S., & Donnenberg, A. D. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.010 · Cited by 168
Guilloton, F., Caron, G., Menard, C., Pangault, C., Amé-Thomas, P., Dulong, J., Vos, J. D., Delphine Rossille, A., Henry, C., Lamy, T., et al. (2012) · Blood · doi:10.1182/blood-2011-08-370908 · Cited by 159
Clinical and prognostic role of annexin A2 in multiple myeloma
Seckinger, A., Meißner, T., Moreaux, J., Depeweg, D., Hillengaß, J., Hose, K., Reme, T. X., Rösen‐Wolff, A., Jauch, A. S., Schnettler, R., et al. (2012) · Blood · doi:10.1182/blood-2012-03-415588 · Cited by 158
Self-citationCancer immunoediting and immune dysregulation in multiple myeloma
Nakamura, K., Smyth, M. J., & Martinet, L. (2020) · Blood · doi:10.1182/blood.2020006540 · Cited by 155
Garayoa, M., Garcia, J. L., Santamaria, C., Garcia-Gomez, A., Blanco, J. F., Pandiella, A., Hernández, J. M., Sanchez-Guijo, F. M., del Cañizo, M.-C., Gutiérrez, N. C., et al. (2009) · Leukemia · doi:10.1038/leu.2009.65 · Cited by 148
Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool
Garcı́a-Castro, J., Trigueros, C., Madrenas, J., Pérez‐Simón, J. A., Rodrı́guez, R., & Menéndez, P. R. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00516.x · Cited by 150
Modeling sarcomagenesis using multipotent mesenchymal stem cells
Rodrı́guez, R., Rubio, R., & Menéndez, P. R. (2011) · Cell Research · doi:10.1038/cr.2011.157 · Cited by 141
Veirman, K. D., Wang, J., Xu, S., Leleu, X. P., Himpe, E., Maes, K., Bruyne, E. D., Valckenborgh, E. V., Vanderkerken, K., Menu, E., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.04.024 · Cited by 141
Human Bone Marrow Is Comprised of Adipocytes with Specific Lipid Metabolism
Attané, C., Estève, D., Chaoui, K., Iacovoni, J. S., Corre, J., Moutahir, M., Valet, P., Burlet‐Schiltz, O., Reina, N., & Muller, C. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.089 · Cited by 143
Self-citationMultiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects
Reagan, M. R., & Ghobrial, I. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2212 · Cited by 139
The mesenchymal stromal cell contribution to homeostasis
Valtieri, M., & Sorrentino, A. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21521 · Cited by 130
Reagan, M. R., Mishima, Y., Glavey, S. V., Zhang, Y., Manier, S., Lu, Z. N., Memarzadeh, M., Zhang, Y. S., Sacco, A., Aljawai, Y. M., et al. (2014) · Blood · doi:10.1182/blood-2014-02-558007 · Cited by 127
Menéndez, P. R., Catalina, P., Rodrı́guez, R., Melen, G. J., Bueno, C., Arriero, M., García‐Sánchez, F., Lassaletta, Á., García‐Sánz, R., & Garcı́a-Castro, J. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20091050 · Cited by 124
Kamdje, A. H. N., Mosna, F., Bifari, F., Lisi, V., Bassi, G., Malpeli, G., Ricciardi, M., Perbellini, O., Scupoli, M. T., Pizzolo, G., et al. (2011) · Blood · doi:10.1182/blood-2010-12-326694 · Cited by 119
Markovina, S. S., Callander, N. S., O’Connor, S. L., Xu, G., Shi, Y., Leith, C. P., Kim, K., Trivedi, P., Kim, J., Hematti, P., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-176 · Cited by 113
Cytokine regulation networks in the cancer microenvironment
Sheu, B. (2008) · Frontiers in bioscience · doi:10.2741/3152 · Cited by 116
Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?
Xu, S., Veirman, K. D., Becker, A. D., Vanderkerken, K., & Riet, I. V. (2018) · Leukemia · doi:10.1038/s41375-018-0061-9 · Cited by 112
CD19−CD45low/−CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells
Kim, D., Park, C. Y., Medeiros, B. C., & Weissman, I. L. (2012) · Leukemia · doi:10.1038/leu.2012.140 · Cited by 108
Evidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells
André, T., Meuleman, N., Stamatopoulos, B., De Bruyn, C., Pieters, K., Bron, D., & Lagneaux, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059756 · Cited by 107
Noll, J. E., Williams, S. A., Tong, C. M., Wang, H., Quach, J., Purton, L. E., Pilkington, K. R., To, L. B., Evdokiou, A., Gronthos, S., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.090977 · Cited by 106
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
Hose, D., Reme, T. X., Meißner, T., Moreaux, J., Seckinger, A., Lewis, J., Beneš, V., Benner, A., Hundemer, M., Hielscher, T., et al. (2009) · Blood · doi:10.1182/blood-2008-09-178350 · Cited by 105
Self-citationThe molecular characterization and clinical management of multiple myeloma in the post-genome era
Zhou, Y., Barlogie, B., & Shaughnessy, J. D. (2009) · Leukemia · doi:10.1038/leu.2009.160 · Cited by 107
Xu, S., Menu, E., Becker, A. D., Van Camp, B., Vanderkerken, K., & Van Riet, I. (2012) · Stem Cells · doi:10.1002/stem.787 · Cited by 103
Corre, J., Labat, E., Espagnolle, N., Hébraud, B., Avet‐Loiseau, H., Roussel, M., Huynh, A., Gadelorge, M., Cordelier, P., Klein, B., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-0188 · Cited by 106
Self-citationGiallongo, C., Tibullo, D., Parrinello, N. L., Cava, P. L., Rosa, M. D., Bramanti, V., Raimondo, C. D., Conticello, C., Chiarenza, A., Palumbo, G. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7969 · Cited by 103
Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells
Figueroa, E. F., Montesinos, J. J., Flores-Guzmán, P., Gutiérrez-Espíndola, G. R., Arana-Trejo, R. M., Castillo-Medina, S., Pérez-Cabrera, A., Hernández-Estévez, É., Arriaga‐Pizano, L., & Mayani, H. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.02.013 · Cited by 100
Corradi, G., Baldazzi, C., Očadlíková, D., Marconi, G., Parisi, S., Testoni, N., Finelli, C., Cavo, M., Curti, A., & Ciciarello, M. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-1013-z · Cited by 102
Pennisi, A., Ling, W., Li, X., Khan, S., Shaughnessy, J. D., Barlogie, B., & Yaccoby, S. (2009) · Blood · doi:10.1182/blood-2009-01-201954 · Cited by 96
de la Guardia, R. D., López‐Millán, B., Lavoie, J. R., Bueno, C., Castaño, J., Gómez-Casares, M., Vives, S., Palomo, L., Juan, M., Delgado, J., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.04.019 · Cited by 99
Advances in the understanding of myeloma bone disease and tumour growth
Yaccoby, S. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08141.x · Cited by 96
Giuliani, M., Janji, B., & Berchem, G. (2017) · Oncotarget · doi:10.18632/oncotarget.15234 · Cited by 91
Epigenetic interplay between immune, stromal and cancer cells in the tumor microenvironment
García-Gómez, A., Rodríguez‐Ubreva, J., & Ballestar, E. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.02.013 · Cited by 88
Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments
Hu, J., & Hu, W.-X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.020 · Cited by 84
Li, X., Ling, W., Pennisi, A., Wang, Y., Khan, S., Heidaran, M. A., Pal, A., Zhang, X., He, S., Zeitlin, A., et al. (2010) · Stem Cells · doi:10.1002/stem.572 · Cited by 83
Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis
Pasquet, M., Golzio, M., Mery, E., Rafii, A., Benabbou, N., Mirshahi, P., Hennebelle, I., Bourin, P., Allal, B., Teissie, J., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.24886 · Cited by 82
Self-citationTanno, T., Lim, Y., Wang, Q., Chesi, M., Bergsagel, P. L., Matthews, G., Johnstone, R. W., Ghosh, N., Borrello, I., Huff, C. A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-524025 · Cited by 82
Xu, S., Santini, G., Veirman, K. D., Broek, I. V., Leleu, X. P., Becker, A. D., Camp, B. V., Vanderkerken, K., & Riet, I. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079752 · Cited by 82
Isidori, A., Salvestrini, V., Ciciarello, M., Loscocco, F., Visani, G., Parisi, S., Lecciso, M., Očadlíková, D., Rossi, L., Gabucci, E., et al. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.958464 · Cited by 85
Mesenchymal stromal cells’ role in tumor microenvironment: involvement of signaling pathways
Kamdje, A. H. N., Kamga, P. T., Simo, R. T., Vecchio, L., Etet, P. F. S., Jm, M., Bassi, G., Lukong, K. E., Goel, R. K., Amvene, J. M., et al. (2017) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0033 · Cited by 81
Panaroni, C., Yee, A. J., & Raje, N. S. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0397-5 · Cited by 82
Soluble Factors on Stage to Direct Mesenchymal Stem Cells Fate
Sobacchi, C., Palagano, E., VILLA, A. M., & Menale, C. (2017) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2017.00032 · Cited by 80
Bueno, C., Montes, R., Catalina, P., Rodrı́guez, R., & Menéndez, P. R. (2010) · Leukemia · doi:10.1038/leu.2010.284 · Cited by 79
Seckinger, A., Meißner, T., Moreaux, J., Goldschmidt, H., Fuhler, G. M., Benner, A., Hundemer, M., Reme, T. X., Shaughnessy, J. D., Barlogie, B., et al. (2009) · Oncogene · doi:10.1038/onc.2009.257 · Cited by 79
Self-citationFowler, J. A., Mundy, G. R., Lwin, S. T., & Edwards, C. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2067 · Cited by 77
Gregory, C., Lee, N., Smolarz, A., Olson, S., David, O., Reiser, J., Kutner, R., Daw, N., Prockop, D., & Horwitz, E. (2007) · Nature Precedings · doi:10.1038/sj.bjc.6604069 · Cited by 77
Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects
García-Gómez, A., Ocio, E. M., Crusoé, E. D. Q., Santamaría, C., Hernández‐Campo, P. M., Blanco, J. F., Sanchez-Guijo, F. M., Hernández‐Iglesias, T., Briñón, J. G., Fisac-Herrero, R. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034914 · Cited by 76
Mesenchymal stromal cells as cancer promoters
Antoon, R., Overdevest, N., Saleh, A. H., & Keating, A. (2024) · Oncogene · doi:10.1038/s41388-024-03183-1 · Cited by 75
Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma
Abe, M. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0949-x · Cited by 75
Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model
Braham, M. V. J., Minnema, M. C., Aarts‐Riemens, T., Sebestyén, Z., Straetemans, T., Vyborova, A., Kuball, J. H. E., Öner, F. C., Robin, C., & Alblas, J. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1434465 · Cited by 73
Bret, C., Hose, D., Reme, T. X., Sprynski, A. C., Mahtouk, K., Schved, J., Quittet, P., Rossi, J., Goldschmidt, H., & Klein, B. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07633.x · Cited by 76
Self-citationAdamik, J., Jin, S., Sun, Q., Zhang, P., Weiss, K. R., Anderson, J. L., Silbermann, R., Roodman, G. D., & Galson, D. L. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0242-t · Cited by 73
Westhrin, M., Moen, S. H., Holien, T., Mylin, A. K., Heickendorff, L., Olsen, O. E., Sundan, A., Turesson, I., Gimsing, P., Waage, A., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.124511 · Cited by 72
Chandran, P., Le, Y., Li, Y., Sabloff, M., Mehic, J., Rosu‐Myles, M., & Allan, D. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.01.013 · Cited by 72
Jakubı́ková, J., Cholujová, D., Hideshima, T., Gronesova, P., Šoltýsová, A., Harada, T., Joo, J., Kong, S., Szalat, R. E., Richardson, P. G. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12643 · Cited by 78
Moreaux, J., Hose, D., Kassambara, A., Reme, T. X., Moine, P., Requirand, G., Goldschmidt, H., & Klein, B. (2010) · Blood · doi:10.1182/blood-2010-04-279760 · Cited by 72
Self-citationGrisendi, G., Annerén, C., Cafarelli, L., Sternieri, R., Veronesi, E., Cervo, G. L., Luminari, S., Maur, M., Frassoldati, A., Palazzi, G., et al. (2010) · Cytotherapy · doi:10.3109/14653241003649510 · Cited by 71
Dynamic interplay between bone and multiple myeloma: Emerging roles of the osteoblast
Reagan, M. R., Liaw, L., Rosen, C. J., & Ghobrial, I. M. (2015) · Bone · doi:10.1016/j.bone.2015.02.021 · Cited by 68
Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?
Noll, J. E., Williams, S. A., Purton, L. E., & Zannettino, A. C. W. (2012) · Blood Cancer Journal · doi:10.1038/bcj.2012.38 · Cited by 68
Xu, S., De Veirman, K., Evans, H., Santini, G. C., Vande Broek, I., Leleu, X., De Becker, A., Van Camp, B., Croucher, P., Vanderkerken, K., et al. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.182 · Cited by 64
Zdzisińska, B., Bojarska-Junak, A. A., Dmoszyńska, A., & Kandefer‐Szerszeń, M. (2008) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-008-0022-5 · Cited by 63
Wang, J., Liao, L., Wang, S., & Tan, M. J. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.01.218 · Cited by 63
Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment
Poggi, A. D., & Giuliani, M. (2016) · Vaccines · doi:10.3390/vaccines4040041 · Cited by 64
Todoerti, K., Lisignoli, G., Storti, P., Agnelli, L., Novara, F., Manferdini, C., Codeluppi, K., Colla, S., Crugnola, M., Abeltino, M., et al. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.11.009 · Cited by 63
Mahtouk, K., Moreaux, J., Hose, D., Reme, T. X., Meißner, T., Jourdan, M., Rossi, J. F., Pals, S. T., Goldschmidt, H., & Klein, B. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-198 · Cited by 64
Self-citationThe emerging role of exosomes in multiple myeloma
Moloudizargari, M., Abdollahi, M. R., Asghari, M. H., Zimța, A., Berindan‐Neagoe, I., & Nabavi, S. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100595 · Cited by 62
Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis
Balakumaran, A., Robey, P. G., Fedarko, N. S., & Landgren, O. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.31 · Cited by 61
Zhou, F., Meng, S., Song, H., & Claret, F. X. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.08.002 · Cited by 62
McNee, G. S., Eales, K. L., Wei, W., Williams, D., Barkhuizen, A., Bartlett, D. B., Essex, S., Anandram, S., Filer, A. D., Moss, P. A. H., et al. (2016) · Leukemia · doi:10.1038/leu.2016.187 · Cited by 57
Garcia-Gomez, A., Li, T., de la Calle-Fabregat, C., Rodríguez-Ubreva, J., Ciudad, L., Català-Moll, F., Godoy-Tena, G., Martín-Sánchez, M., San-Segundo, L., Muntión, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20715-x · Cited by 57
Pacini, S. (2014) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2014.00050 · Cited by 53
Xu, S., Evans, H., Buckle, C., Veirman, K. D., Hu, J., Xu, D., Menu, E., Becker, A. D., Broek, I. V., Leleu, X. P., et al. (2012) · Leukemia · doi:10.1038/leu.2012.126 · Cited by 55
Tumor–host cell interactions in the bone disease of myeloma
Fowler, J. A., Edwards, C. M., & Croucher, P. I. (2010) · Bone · doi:10.1016/j.bone.2010.06.029 · Cited by 55
Mesenchymal stem cells and their microenvironment
Ingrid, U. S. (2011) · Frontiers in bioscience · doi:10.2741/3853 · Cited by 56
Bone marrow inflammation in haematological malignancies
de Jong, M. M. E., Chen, L., Raaijmakers, M. H. G. P., & Cupedo, T. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01003-x · Cited by 54
Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms
Coker, W. J., Jeter, A., Schade, H. H., & Kang, Y. (2013) · Biomarker Research · doi:10.1186/2050-7771-1-8 · Cited by 54
Multiple myeloma: the bone marrow microenvironment and its relation to treatment
Andrews, S. W., Kabrah, S. M., May, J. E., Donaldson, C., & Morse, H. (2013) · British Journal of Biomedical Science · doi:10.1080/09674845.2013.11669945 · Cited by 52
Drake, M. T. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2387 · Cited by 53
García-Gómez, A., Rivas, J. D. L., Ocio, E. M., Dı́az-Rodrı́guez, E., Montero, J. C., Martín, M., Blanco, J. F., Sanchez-Guijo, F. M., Pandiella, A., Miguel, J. F. S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2058 · Cited by 55
The osteoblastic niche in the context of multiple myeloma
Toscani, D., Bolzoni, M., Accardi, F., Aversa, F., & Giuliani, N. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12578 · Cited by 52
Osteoblastogenesis and tumor growth in myeloma
Yaccoby, S. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903503438 · Cited by 52
Wang, Q., Shi, Q., Lu, J., Wang, Z., & Hou, J. (2022) · International Journal of Cancer · doi:10.1002/ijc.34214 · Cited by 51
Thudi, N. K., Martin, C. K., Nadella, M. V. P., Fernández, S., Werbeck, J. L., Pinzone, J. J., & Rosol, T. J. (2008) · The Prostate · doi:10.1002/pros.20776 · Cited by 49
Maiso, P., Mogollón, P., Ocio, E. M., & Garayoa, M. (2021) · Cancers · doi:10.3390/cancers13112542 · Cited by 48
Chen, D., Tang, P., Liu, L., Wang, F., Xing, H., Sun, L., & Jiang, Z. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1442624 · Cited by 48
Slany, A., Haudek‐Prinz, V. J., Meshcheryakova, A., Bileck, A., Lamm, W. W., Zielinski, C. C., Gerner, C., & Drach, J. W. (2013) · Journal of Proteome Research · doi:10.1021/pr400881p · Cited by 47
Metadata
- Authors
- Corre, J., Mahtouk, K., Attal, M., Gadelorge, M., Huynh, A., Fleury-Cappellesso, S., Danho, C., Laharrague, P., Klein, B., Rème, T., & Bourin, P.
- Affiliations
- Établissement Français du Sang (FR)
- Inserm (FR)
- Hôpital Purpan (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Bourin, P
- Venue
- Leukemia
- Published
- 2007-03-08
- Volume
- 21
- Issue
- 5
- Pages
- 1079-1088
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC2346535
- OpenAlex
- W2048064990
- Cited by
- 328
- References
- 62
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 13 · 2023: 11 · 2022: 12 · 2021: 20 · 2020: 18 · 2019: 10 · 2018: 18 · 2017: 21 · 2016: 21 · 2015: 18 · 2014: 23 · 2013: 25 · 2012: 25
- FWCI
- 13.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- multiple myeloma, bone marrow mesenchymal stem cells, tumor microenvironment, monoclonal gammopathy of undetermined significance, gene expression profiling, interleukin-6, DKK1, GDF15, angiogenesis, osteogenic differentiation
- MeSH terms
- Adult, Aged, Bone Marrow Cells, Cell Differentiation, Female, Hematopoiesis, Humans, Male, Middle Aged, Multiple Myeloma, Osteoblasts, Cytokines, Gene Expression Profiling, Cell Proliferation, Growth Differentiation Factor 15, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
